Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 1
1970 2
1971 1
1973 4
1975 6
1976 13
1977 11
1978 16
1979 13
1980 17
1981 13
1982 13
1983 8
1984 14
1985 17
1986 11
1987 11
1988 16
1989 13
1990 16
1991 17
1992 12
1993 18
1994 7
1995 9
1996 11
1997 10
1998 8
1999 4
2000 10
2001 2
2002 13
2003 7
2004 8
2005 7
2006 3
2007 7
2008 11
2009 12
2010 15
2011 13
2012 15
2013 11
2014 8
2015 13
2016 11
2017 9
2018 9
2019 12
2020 13
2021 8
2022 12
2023 5
2024 14
2025 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

544 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial.
Easterling T, Mundle S, Bracken H, Parvekar S, Mool S, Magee LA, von Dadelszen P, Shochet T, Winikoff B. Easterling T, et al. Lancet. 2019 Sep 21;394(10203):1011-1021. doi: 10.1016/S0140-6736(19)31282-6. Epub 2019 Aug 1. Lancet. 2019. PMID: 31378394 Free PMC article. Clinical Trial.
The primary outcome was significantly more common in women in the nifedipine group than in those in the methyldopa group (249 [84%] women vs 230 [76%] women; p=0.03). However, the primary outcome did not differ between the nifedipine and labetalol groups (249 [84%] women v …
The primary outcome was significantly more common in women in the nifedipine group than in those in the methyldopa group (249 [84%] w …
Methyldopa for primary hypertension.
Mah GT, Tejani AM, Musini VM. Mah GT, et al. Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD003893. doi: 10.1002/14651858.CD003893.pub3. Cochrane Database Syst Rev. 2009. PMID: 19821316 Free PMC article.
Data from six of the twelve trials (N=231) were combined to evaluate the blood pressure lowering effects of methyldopa compared to placebo. This meta-analysis shows that methyldopa at doses ranging from 500-2250 mg daily lowers systolic and diastolic blood pressure …
Data from six of the twelve trials (N=231) were combined to evaluate the blood pressure lowering effects of methyldopa compared to pl …
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
Soileau MJ, Aldred J, Budur K, Fisseha N, Fung VS, Jeong A, Kimber TE, Klos K, Litvan I, O'Neill D, Robieson WZ, Spindler MA, Standaert DG, Talapala S, Vaou EO, Zheng H, Facheris MF, Hauser RA. Soileau MJ, et al. Lancet Neurol. 2022 Dec;21(12):1099-1109. doi: 10.1016/S1474-4422(22)00400-8. Lancet Neurol. 2022. PMID: 36402160 Clinical Trial.
Oral Antihypertensives for Nonsevere Pregnancy Hypertension: Systematic Review, Network Meta- and Trial Sequential Analyses.
Bone JN, Sandhu A, Abalos ED, Khalil A, Singer J, Prasad S, Omar S, Vidler M, von Dadelszen P, Magee LA. Bone JN, et al. Hypertension. 2022 Mar;79(3):614-628. doi: 10.1161/HYPERTENSIONAHA.121.18415. Epub 2022 Jan 4. Hypertension. 2022. PMID: 35138877 Free PMC article.
All commonly prescribed antihypertensives (labetalol, other beta-blockers, methyldopa, calcium channel blockers, and mixed/multi-drug therapy) versus placebo/no therapy reduced the risk of severe hypertension by 30% to 70%. Labetalol decreased proteinuria/preeclampsia (odd …
All commonly prescribed antihypertensives (labetalol, other beta-blockers, methyldopa, calcium channel blockers, and mixed/multi-drug …
Levodopa and the progression of Parkinson's disease.
Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group. Fahn S, et al. N Engl J Med. 2004 Dec 9;351(24):2498-508. doi: 10.1056/NEJMoa033447. N Engl J Med. 2004. PMID: 15590952 Free article. Clinical Trial.
Oral antihypertensive treatment during pregnancy: a systematic review and network meta-analysis.
Hup RJ, Damen JAA, Terstappen J, Klein Haneveld MJ, Terstappen F, Magee LA, Lely AT, Depmann M. Hup RJ, et al. Am J Obstet Gynecol. 2025 Oct;233(4):250-262. doi: 10.1016/j.ajog.2025.04.011. Epub 2025 Apr 10. Am J Obstet Gynecol. 2025. PMID: 40216176 Free article.
Therefore, this systematic review and network meta-analysis aims to determine the effects of antenatal treatment with methyldopa, labetalol, or nifedipine for hypertensive disorders of pregnancy regarding maternal or fetal/neonatal morbidity and mortality. ...Compared to p …
Therefore, this systematic review and network meta-analysis aims to determine the effects of antenatal treatment with methyldopa, lab …
Methyldopa versus labetalol or no medication for treatment of mild and moderate chronic hypertension during pregnancy: a randomized clinical trial.
Rezk M, Emarh M, Masood A, Dawood R, El-Shamy E, Gamal A, Badr H. Rezk M, et al. Hypertens Pregnancy. 2020 Nov;39(4):393-398. doi: 10.1080/10641955.2020.1791902. Epub 2020 Jul 22. Hypertens Pregnancy. 2020. Retraction in: Hypertens Pregnancy. 2023 Dec;42(1):2268991. doi: 10.1080/10641955.2023.2268991. PMID: 32697618 Free article. Retracted. Clinical Trial.
OBJECTIVE: to assess the maternal and fetal outcome in women with mild to moderate chronic hypertension on antihypertensive drug (methyldopa or labetalol) therapy compared to no medication. METHODS: This multicenter randomized clinical study was conducted at Menoufia Unive …
OBJECTIVE: to assess the maternal and fetal outcome in women with mild to moderate chronic hypertension on antihypertensive drug (methyld …
Methyldopa versus nifedipine or no medication for treatment of chronic hypertension during pregnancy: A multicenter randomized clinical trial.
Salama M, Rezk M, Gaber W, Hamza H, Marawan H, Gamal A, Abdallah S. Salama M, et al. Pregnancy Hypertens. 2019 Jul;17:54-58. doi: 10.1016/j.preghy.2019.05.009. Epub 2019 May 9. Pregnancy Hypertens. 2019. PMID: 31487657 Clinical Trial.
OBJECTIVE: To assess the maternal and fetal outcome in women with mild to moderate chronic hypertension on antihypertensive drug (methyldopa or nifedipine) therapy compared to no medication. METHODS: This multicenter randomized clinical trial was conducted at Menoufia Univ …
OBJECTIVE: To assess the maternal and fetal outcome in women with mild to moderate chronic hypertension on antihypertensive drug (methyld …
544 results